Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05472519
Other study ID # 69HCL22_0016
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 17, 2022
Est. completion date June 7, 2023

Study information

Verified date June 2023
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Loeys-Dietz syndrome (LDS) is a rare vascular genetic disorder (estimated prevalence 1/25,000-1/100,000) due primarily to mutations in the Transforming growth factor beta (TGF-β) cytokine receptor 1 and 2 genes. In addition to a common vascular phenotype with Marfan syndrome (dilatation of the ascending aorta, arachnodactyly, lens dislocation), patients present specific malformations (bifid uvula, hypertelorism, tortuous arteries) and immuno-allergic manifestations (asthma, eczema, food allergy, eosinophilic esophagitis, chronic inflammatory bowel disease). Pathophysiologically, LDS appears to be associated with hyperactivation of the intracellular TGF-β signaling pathway in a manner similar to Marfan syndrome, as evidenced by increased intracellular phosphorylated Smad2/3 (pSmad2/3) in lymphocytes. The immuno-allergic complications appear paradoxical because of the major immunosuppressive role of this cytokine on lymphoid and myeloid immune lineages. The biological description of immunological abnormalities associated with LDS is based on a single 2013 study that found increased regulatory T (Treg) and Th2 lymphocyte polarizations, as well as increased circulating eosinophil and total IgE levels. In order to better understand the underlying mechanisms, the investigators propose to perform a descriptive clinical-biological study to identify and study the immune subpopulations most impacted by the causative mutations of LDS.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date June 7, 2023
Est. primary completion date June 7, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years to 86 Years
Eligibility Inclusion Criteria: For patients with Loeys-Dietz syndrome: - Patients aged = 5 years with Loeys-Dietz syndrome with a diagnosis confirmed by the presence of a TGF-ßR 1 or R2 mutation known to be pathogenic to patients. - Free, informed and signed consent from the patient or both parents or legal guardians for minor patients. - Patient affiliated to a social security system or similar. For healthy volunteers: - Subjects aged = 5 years. - Free, informed and signed consent of the witness, or if applicable of both parents or legal representatives for minors. - Patient affiliated to a social security system or similar. Exclusion Criteria: For patients with Loeys-Dietz syndrome: - Patient with an evolving or recently healed (< 3 months) cancer that could alter the immunologic profile. - Patient with an evolving or recently healed (< 3 months) infection that could alter the immunologic profile. - Patient with a weight of less than 20 kg. - Pregnant woman. - Patient participating in another research study with an exclusion period exclusion period still in progress. For healthy volunteers: - Subject with an active or recently cured (< 3 months) cancer that could alter the immunologic profile. - Subject with an active or recently healed (< 3 months) infection that could alter the immunological profile. - Patient with a weight of less than 20 kg. - Pregnant woman. - Subject participating in another research study with an exclusion period exclusion period still in progress. - Persons under court protection.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
blood samples
Only one visit for each participant: A large majority of visits will be part of patients' usual care. Medical examination : weight, gender, blood pressure, medical history Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma
blood samples
Only one visit for each participant: Medical examination : weight, gender, blood pressure, medical history Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma

Locations

Country Name City State
France Hôpital Femme-Mère-Enfant / Centre de Compétences pour le syndrome de Marfan et apparentés Bron

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of circulating TFH lymphocyte subpopulation. Measured from the Blood samples of each patients / volunteers. Day 1
Secondary Intracellular pSmad2/3 labeling level of circulating TFH lymphocytes. Measured from the Blood samples of each patients / volunteers. Day 1
Secondary Identification of Immuno-allergic pathologies Identification of Immuno-allergic, serious infectious pathologies (diagnostic criteria, severity criteria, treatment, current activity) in LDS patients. Day 1
Secondary Identification of serious infectious pathologies Identification of serious infectious pathologies (diagnostic criteria, severity criteria, treatment, current activity) in LDS patients. Day 1
Secondary Identification of Vascular complications Identification of Vascular, morpho-skeletal complications (diagnostic criteria, severity criteria, treatment, current activity) current course) in patients with LDS. Day 1
Secondary Identification morpho-skeletal complications Identification of morpho-skeletal complications (diagnostic criteria, severity criteria, treatment, current activity) current course) in patients with LDS. Day 1
See also
  Status Clinical Trial Phase
Completed NCT01322165 - National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions N/A
Active, not recruiting NCT05980104 - Single-Session "Empowered Relief" Class for Marfan Syndrome and Related Conditions N/A
Recruiting NCT02050113 - Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices N/A
Recruiting NCT02504853 - Natural History and Genetics of Food Allergy and Related Conditions
Completed NCT02213484 - Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes N/A
Recruiting NCT03440697 - Pathogenetic Basis of Aortopathy and Aortic Valve Disease
Not yet recruiting NCT05389865 - Proximal Aortopathy in Scotland - Epidemiology and Surgical Outcomes